<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362103">
  <stage>Registered</stage>
  <submitdate>24/02/2012</submitdate>
  <approvaldate>2/03/2012</approvaldate>
  <actrnumber>ACTRN12612000261819</actrnumber>
  <trial_identification>
    <studytitle>Pilot Study of the Effects of GC811007 Administration on Copper and Trace Metal Metabolism in Non-diabetic Subjects and Patients with Type 2 Diabetes Mellitus: A Dose-response Sub-study</studytitle>
    <scientifictitle>Pilot Study of the Effects of GC811007 Administration on Copper and Trace Metal Metabolism in Non-diabetic Subjects and Patients with Type 2 Diabetes Mellitus: A Dose-response Sub-study of TETA on urinary copper excretion</scientifictitle>
    <utrn />
    <trialacronym>TRACE-Dose Rising study</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type-2 Diabetes Mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This was an open-label, sequential, escalating, dose-response study in which 14 adult males (7 diabetic and 7 non-diabetic subjects) were assessed. Four escalating doses (300, 600, 1200, and 2400 mg) of GC811007 taken as 300mg capsules, were administered to each subject daily; each dose was taken once-daily before breakfast for 7 days, with a 6-week washout period between each dose; 24-h urine collections at baseline and on the final day of each dosing period, were performed to measure trace element excretion.</interventions>
    <comparator>Dose comparison of diabetic versus healthy particpants. All participants receive all doses.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Effect of 4 escalating doses of GC811007 on Urinary Copper excretion over 24 hrs, on Day 1 and Day 7 of each treatment week.</outcome>
      <timepoint>urine copper excretion collected over 24 hrs, on Day 1 and Day 7 of each treatment week.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of 4 escalating doses of GC811007 on Urinary Zinc and Iron excretion over 24 hrs, on Day 1 and Day 7 of each treatment week.</outcome>
      <timepoint>Urine metal excretion collected over 24 hrs, on Day 1 and Day 7 of each treatment week.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with type-2 diabetes mellitus and healthy non-diabetic subjects with normal glucose tolerance; normal ECG; normal serum levels of Fe and ferritin</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Subjects who had not participated in a previous 12-day residential study of trace metal balance; eligible subjects who did not have normal glucose tolerance and ECG and normal levels of serum Fe and Ferritin</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>13/08/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>14</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Protemix Corporation Ltd.</primarysponsorname>
    <primarysponsoraddress>PO Box 2165, Shortland Street
Auckland 1140</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Protemix Corporation</fundingname>
      <fundingaddress>Protemix Corporation Ltd.
PO Box 2165, Shortland Street
Auckland 1140</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study was designed to explore the dose-rising effects of GC811007 on trace metal metabolism in patients with T2DM and healthy non-diabetic subjects; specifically we wanted to investigate the effects of 4 doses of GC811007 on trace metal urine excretion over a period of 7 days. We hypothesised that increasing doses of GC811007 would increase urine copper losses in a dose-dependent manner</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland Health &amp; Disabilities Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>2001/026</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Garth Cooper</name>
      <address>School of Biological Sciences
University of Auckland
Private Bag 92 019
Auckland 1142</address>
      <phone>+64 (9) 923 7239</phone>
      <fax />
      <email>g.cooper@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sally Poppitt</name>
      <address>School of Biological Sciences
University of Auckland
Private Bag 92 019
Auckland 1142</address>
      <phone>+64 (9) 630 5160</phone>
      <fax />
      <email>s.poppitt@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>